Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

To compare the efficacy of triple therapy (metformin/exenatide/pioglitazone) versus stepwise conventional therapy (metformin → glipizide → glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug‐naïve patients with type 2 diabetes.

[1]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[2]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[3]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[4]  E. Boyko,et al.  The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999–2002 , 2006, The American Journal of Gastroenterology.

[5]  A. Suzuki,et al.  Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps , 2019, Hepatology.

[6]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[7]  Jen-Jung Pan,et al.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD , 2013, Biomarker Research.

[8]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[9]  A. Lonardo,et al.  Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease , 2021, Diagnostics.

[10]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[11]  A. Gastaldelli,et al.  Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease , 2016, Hepatology.

[12]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[13]  Y. Miyazaki,et al.  The Effect of Pioglitazone on the Liver , 2006, Diabetes Care.

[14]  M. Matsuda,et al.  Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.

[15]  J. Hardies,et al.  Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[17]  R. DeFronzo,et al.  Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial , 2015, Diabetes, obesity & metabolism.

[18]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[19]  R. Pettigrew,et al.  Liver metabolite concentrations measured with 1H MR spectroscopy. , 2012, Radiology.

[20]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[21]  Lee-Jen Wei,et al.  Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[23]  K. Cusi,et al.  Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[24]  A. Gamst,et al.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. , 2013, Radiology.

[25]  P. Hayes,et al.  Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.

[26]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[27]  K. Cusi,et al.  Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.

[28]  K. Cusi,et al.  Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. , 2020, Journal of hepatology.

[29]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[30]  A. Gastaldelli,et al.  Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications , 2020, BMJ Open Diabetes Research & Care.

[31]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[32]  K. Cusi,et al.  Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.

[33]  R. DeFronzo,et al.  Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes , 2017, The FEBS journal.

[34]  A. Zarrinpar,et al.  Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population , 2021, Frontiers in Medicine.

[35]  K. Cusi,et al.  Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus , 2018, Diabetes, obesity & metabolism.

[36]  Z. Younossi,et al.  Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. , 2019, Diabetes Care.

[37]  Hirokazu Takahashi,et al.  Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[38]  Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease. , 2020, Molecular metabolism.

[39]  C. Sirlin,et al.  Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. , 2019, Journal of hepatology.

[40]  A. Gastaldelli.  Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? , 2017, Clinical science.

[41]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[42]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[43]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[44]  R. DeFronzo,et al.  Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes , 2019, Diabetes & vascular disease research.

[45]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.